LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its Buffalo division (Cognigen Corporation) has released Version 1.5 of KIWI™, a private cloud-based platform to efficiently and consistently organize, process, evaluate, and communicate modeling and simulation results.
Mr. David Fox, Senior Software Engineer in the Buffalo division of Simulations Plus, said, “The KIWI development team is focused on creating a collaborative working environment that enhances communications between scientists, development teams and management. Our software team regularly observes the interdisciplinary interactions between our project teams and our clients, and these experiences serve as the blueprint for enhancements to the KIWI program. The release of KIWI Version 1.5 reflects our ongoing commitment to creating an innovative and validated environment in support of modeling and simulation activities.”
Dr. Sébastian Bihorel, Associate Director, Pharmacometrics, added, “This new version of KIWI introduces major enhancements in the functionality of visualization tools offered by the platform. From the perspective of a scientist, the ease of creating plots and comparing them across multiple models greatly simplifies and accelerates the process of model refinement. In addition, analysts can now conveniently copy visualization preferences across projects, improving consistency and facilitating collaboration and communication with clients and colleagues.”
Ted Grasela, President of Simulations Plus, added, “We are excited to continue to add to our visualization module of KIWI. The visualization of data and model results is a valuable way to spark conversations with interdisciplinary teams and a critical step in demonstrating the value of modeling and simulation in team decision-making. We continue to receive positive feedback about the functionality we have implemented in KIWI and look forward to the continuing evolution of the program.”
About Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect,” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.